3634 results for «656»
3634 results
All you need to know about redo TAVI
15 Feb 2026 – From PCR Tokyo Valves 2026
This comprehensive session on redo Transcatheter Aortic Valve Implantation (TAVI) covers critical aspects beyond coronary obstruction risk, including detailed pre-procedural analysis, valve sizing, and innovative procedural techniques such as leaflet modification and optimal angle placement. Post-procedural considerations like antithrombotic therapy and patient-prosthesis mismatch are also thoroughly...
PCR Tokyo Valves 2026 Closing Ceremony
15 Feb 2026 – From PCR Tokyo Valves 2026
The Closing Ceremony marks the conclusion of this cardiology conference, providing a formal wrap-up and reflection on the key highlights and advancements presented throughout the event. It serves as an opportunity to acknowledge contributors and set the stage for future initiatives in interventional cardiology.
Procedural optimisation for enhanced acute and long-term outcomes
14 Feb 2026 – From PCR Tokyo Valves 2026
This session emphasizes procedural optimization in TAVI to enhance both acute and long-term outcomes. It highlights critical factors such as valve sizing, expansion, implantation depth, and commissural alignment. Practical techniques for pre- and post-dilatation alongside commissural alignment are demonstrated through real cath lab cases, underscoring their...
Contemporary approach in the treatment of calcified coronary artery disease
28 Feb 2026 – From Euro4C Annual Meeting 2026
Adopt a contemporary approach to managing calcified coronary artery disease by leveraging high-definition IVUS for lesion assessment and morphology evaluation. Learn to tailor calcium modification strategies based on IVUS findings and combine available tools to optimize treatment outcomes according to patient and lesion profiles.
Welcome to the Euro4C Annual Meeting 2026
27 Feb 2026 – From Euro4C Annual Meeting 2026
This introductory session sets the stage for a comprehensive exploration of interventional cardiology topics, providing attendees with an overview and framework for the upcoming educational content.
How to correct incomplete crush and how to prevent lack of carina coverage
- Differentiating between complete and incomplete crush
- The importance of sequential crush and bigger balloons, adequately sized according to proximal vessel diameter
Commented by Goran Stankovic and William Wijns
Part 2 of a 3-part series:
Previous episode: DK Crush like you’ve never seen it before
Coming up next: Main vessel stenting in DK-Crush, lessons...
Main vessel stenting in DK-Crush: lessons from stepwise provisional strategy
- Optimisation of side branch stenting
- How to optimally deploy the second stent
Commented by Goran Stankovic and William Wijns
Part 3 of a 3-part series. Previous episode: How to correct incomplete crush and how to prevent lack of carina coverage
Miscellaneous complications: my worst nightmare
15 Feb 2026 – From PCR Tokyo Valves 2026
Explore the prevention and management of complications arising from transcatheter interventions in structural heart disease through challenging case analyses. This session presents real-world scenarios addressing complications encountered during TAVI, mitral, and tricuspid procedures, highlighting strategies to anticipate and manage these critical events effectively.
Procedural imaging for tricuspid valve interventions
15 Feb 2026 – From PCR Tokyo Valves 2026
Dedicated to procedural imaging for tricuspid valve interventions, this session elucidates anatomical and pathophysiological features critical for successful transcatheter procedures. It emphasizes technical aspects of TEE and ICE imaging, including 3D multiplanar reconstruction, and offers case-based learning to refine imaging skills and optimize procedural outcomes.
Introducing the next era of coronary intravascular lithotripsy: an aero-volution in calcium modification
27 Feb 2026 – From Euro4C Annual Meeting
Explore the next era of coronary intravascular lithotripsy featuring innovative technology for calcium modification. This session covers the unique mechanism of action, practical application in complex cases, and recent clinical evidence supporting its safety and efficacy.
Novel Hertz Contact intravascular lithotripsy: calcium fragmentation with zero trade-offs
27 Feb 2026 – From Euro4C Annual Meeting
This session introduces the novel Hertz Contact intravascular lithotripsy system, designed for effective calcium fragmentation without trade-offs. It covers lesion types amenable to treatment, system mechanism, optimization tips, and discusses real-world cases along with supporting clinical trial evidence.
Mitral and aortic transcatheter valve-in-valve intervention - LIVE case
14 Feb 2026 – From PCR Tokyo Valves 2026
Live case
An 83-year-old male with AF, CKD (stage 3A), preserved LV function, and a history of AVR (27 mm Magna Ease) and MVR (33 mm Magna) in 2014 presented with symptomatic stenosis of the mitral bioprosthesis. A Sapien 3 valve was implanted in the Magna mitral...
PCR Tokyo Valves 2026 Welcome Ceremony
14 Feb 2026 – From PCR Tokyo Valves 2026
The Welcome Ceremony marks the commencement of the conference, setting the stage for an engaging and informative program dedicated to advances in cardiology and interventional techniques. It provides attendees with an overview of the event's objectives and highlights the collaborative spirit of the cardiology community.
Late-breaking trials of PCR Tokyo Valves 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
This session presents pivotal late-breaking trials from PCR Tokyo Valves 2026, offering one-year outcomes and real-world experiences in transcatheter valve therapies. Highlights include the AltaValve early feasibility study on atrial fixation TMVR, invasive registry insights on prosthesis-patient mismatch post-TAVR, and registry data on tricuspid and mitral...
TEER in complex tricuspid regurgitation - LIVE case
14 Feb 2026 – From PCR Tokyo Valves 2026
A 79-year-old male with permanent AF, prior colorectal and prostate cancer, and a Mosaic bioprosthetic mitral valve implanted in 2016, presented with torrential tricuspid regurgitation and preserved LV function.
Three G5 clips were implanted: two anteroseptal (1 XTW and 1 XT) and one posteroseptal XTW.
LIVE Educational Case...
Hot topics and evidence on structural interventions in 2025 and 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
Delve into the emerging clinical evidence and key hot topics shaping transcatheter interventions for aortic, mitral, and tricuspid valve diseases anticipated to influence clinical practice in 2025 and 2026. This session reviews stroke prevention, valve interventions across the three valves, and integrates recent and upcoming data...
Prevention and management of TAVI complications
14 Feb 2026 – From PCR Tokyo Valves 2026
This session addresses the prevention and management of major complications associated with transcatheter aortic valve implantation (TAVI). Attendees will gain a detailed understanding of mechanisms behind cerebral infarction, haemolysis, valve infolding, pacemaker implantation, and valve migration, along with expert strategies for recognition, decision-making, and bailout techniques...
Primary mitral TEER in small anatomy - LIVE case
15 Feb 2026 – From PCR Tokyo Valves 2026
An 89-year-old male with diabetes mellitus, hypertension, chronic kidney disease (eGFR: 46), and CAD with a history of NSTEMI and CTO of the RCA, presented with symptomatic primary mitral regurgitation (P1–P2 prolapse) and preserved LV function (56%).
One Pascal ACE device was implanted.
LIVE Educational Case from Nagoya...
Guidelines update
15 Feb 2026 – From PCR Tokyo Valves 2026
This session reviews the latest updates in the ESC/EACTS guidelines for structural heart disease, emphasizing their clinical implications and future trends. Participants will gain understanding of changes in aortic, mitral, and tricuspid valve recommendations, including new age cutoffs, asymptomatic disease management, and the evolving role of...
Future devices and techniques for structural heart disease
15 Feb 2026 – From PCR Tokyo Valves 2026
This session surveys the future landscape of structural heart disease treatment, addressing current limitations in transcatheter valve technologies and presenting emerging devices and techniques for aortic, mitral, and tricuspid valves. Attendees will gain insights into innovations poised to transform therapeutic options for structural heart disease.
